Clinician’s guide to Renasight results

Empower Gene Table - 81 Gene Panel Additional Cancer Risks

Empower Gene Table - 81 Gene Table by Panel

Empower Gene Table - 40 Gene Multi-Cancer Panel

Patient Access Guide

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Tissue Sample Collection Instructions

Overview document on how Signatera collections a FFPE sample.

Empower 81 Gene Comprehensive Panel Cancer Risks

Empower 81 Gene Comprehensive Panel

Empower Gene Table by Panel

Signatera Altera Empower Requisition Form

Please note: only an authorized healthcare provider can submit a test request for Signatera.

Indications For Use GenNeph

Prospera™ is a donor-derived cell-free DNA (dd-cfDNA) test for assessment of rejection in post-renal-transplant patients.

Signatera™ for early detection of molecular residual disease using ctDNA

Detect residual disease and recurrence early in colorectal cancer (CRC). How often should Signatera be ordered for CRC patients?

Signatera and Altera Insurance Coverage and Billing

The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions. Read our billing guide for information about understanding Natera's genetic testing bill.

Recommended blood draw and testing frequency

Overview document detailing blood draw and testing frequency.

Tumor Genomic Profile

Altera offers a whole exome and transcriptome-based approach for Comprehensive Genomic Profiling (CGP) with boosted >500X coverage for 440 medically important genes.